Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
4.690
+0.150 (3.30%)
Aug 6, 2026, 9:48 AM EDT - Market open
Prelude Therapeutics Revenue
Prelude Therapeutics had revenue of $4.58M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $16.72M, up 138.86% year-over-year. In the year 2025, Prelude Therapeutics had annual revenue of $12.14M with 73.43% growth.
Revenue (ttm)
$16.72M
Revenue Growth
+138.86%
P/S Ratio
26.93
Revenue / Employee
$211,646
Employees
79
Market Cap
465.14M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.14M | 5.14M | 73.43% |
| Dec 31, 2024 | 7.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sutro Biopharma | 99.61M |
| Prothena Corporation | 57.94M |
| Q32 Bio | 53.74M |
| Evommune | 10.00M |
| Ovid Therapeutics | 7.12M |
| Ocugen | 4.47M |
| Inhibikase Therapeutics | 1.00 |
PRLD News
- 8 days ago - Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline - TheFly
- 2 months ago - Prelude Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Prelude Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Prelude Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs - TheFly
- 3 months ago - Prelude Therapeutics reports Q1 EPS (13c), consensus (27c) - TheFly
- 3 months ago - Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Prelude Therapeutics Earnings release: Q1 2026 - Filings